CGEN · Insider Trading
Compugen Ltd
Every open-market purchase and sale reported by CGEN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-30 | Sanford S Zweifach | Director | A | +7,500 | — |
| 2026-07-30 | Anat Cohen-Dayag | Director | A | +100,000 deriv. | — |
| 2026-07-30 | David Silberman | Chief Financial Officer | A | +19,500 | — |
| 2026-07-30 | Savitzky Kinneret Livnat | Director | A | +7,500 | — |
| 2026-07-30 | Eran Ophir | President and CEO | A | +200,000 deriv. | — |
| 2026-07-30 | Mathias Hukkelhoven | Director | A | +7,500 | — |
| 2026-07-30 | Pierre Ferre | Chief Operating Officer | A | +70,000 deriv. | — |
| 2026-07-30 | Eran Perry | Director | A | +7,500 | — |
| 2026-07-30 | Zurit Levine | SVP, Business Development | A | +18,000 | — |
| 2026-07-30 | Gilead Halevy | Director | A | +7,500 | — |
| 2026-07-30 | Russo Sharon Kredo | SVP, Research & Discovery | A | +18,000 | — |
| 2026-07-30 | Michelle Mahler | Chief Medical Officer | A | +13,500 | — |
| 2026-07-13 | Zurit Levine | SVP, Business Development | MIXED | — | −$3.13K |
| 2026-04-27 | Zurit Levine | SVP, Business Development | MIXED | — | −$4.10K |
| 2026-04-27 | Eran Ophir | President and CEO | MIXED | — | −$11.85K |
| 2026-04-15 | Eran Ophir | President and CEO | MIXED | — | −$10.38K |
| 2026-04-15 | Zurit Levine | SVP, Business Development | MIXED | — | −$3.30K |
| 2026-04-15 | Zurit Levine | SVP, Business Development | MIXED | — | −$4.78K |
| 2026-04-13 | Zurit Levine | SVP, Business Development | MIXED | — | −$4.78K |
| 2026-04-09 | Zurit Levine | SVP, Business Development | MIXED | — | −$11.91K |
| 2026-04-03 | Eran Ophir | President and CEO | MIXED | — | −$7.75K |
| 2026-04-03 | Zurit Levine | SVP, Business Development | MIXED | — | −$4.48K |
| 2026-03-30 | Zurit Levine | SVP, Business Development | MIXED | — | −$14.34K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| David Silberman | Chief Financial Officer | 55,000 | $127.05K |
| Zurit Levine | SVP, Business Development | 47,375 | $109.44K |
| Russo Sharon Kredo | SVP, Research & Discovery | 37,500 | $86.62K |
| Michelle Mahler | Chief Medical Officer | 36,625 | $84.60K |
| Savitzky Kinneret Livnat | Director | 20,850 | $48.16K |
| Sanford S Zweifach | Director | 20,180 | $46.62K |
| Gilead Halevy | Director | 18,907 | $43.68K |
| Mathias Hukkelhoven | Director | 17,500 | $40.42K |
| Eran Perry | Director | 17,500 | $40.42K |
| Eran Ophir | President and CEO | 16,375 | $37.83K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CGEN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.